Effect of Selective Mineralocorticoid Receptor Blockade on Flow-Mediated Dilation and Insulin Resistance in Older Adults with Metabolic Syndrome

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 8, 2015, Pages 356-361

  Hwang, Moon Hyon ^a,b   Yoo, Jeung Ki ^a   Luttrell, Meredith ^c   Meade, Thomas H ^d   English, Mark ^d   Christou, Demetra D ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b SolarLight Ltd   (South Korea)

^c UNIVERSITY OF OREGON   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; INSULIN; ISOPROSTANE DERIVATIVE; MINERALOCORTICOID RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE;

ADULT; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VASODILATATION; AGED; ANALOGS AND DERIVATIVES; BLOOD FLOW; DIAGNOSTIC IMAGING; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGED; BRACHIAL ARTERY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OXIDATIVE STRESS; PLACEBOS; REGIONAL BLOOD FLOW; SPIRONOLACTONE; ULTRASONOGRAPHY; VASODILATION;

EID: 84941958336     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0044     Document Type: Article

References (33)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
2. Haffner SM. Risk constellations in patients with the metabolic syndrome: Epidemiology, diagnosis, and treatment patterns. Am J Med 2006;119:S3-S9.
3. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
4. Wong ND, Nelson JC, Granston T, et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: The Multiethnic Study of Atherosclerosis study. JACC Cardiovasc Imaging 2012;5:358-366.
5. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49:403-414.
6. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-3072.
7. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006;48:239-245.
8. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011;13:163-172.
9. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(23 Suppl 1):III27-32.
10. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002;105:2212-2216.
11. Thai HM, Do BQ, Tran TD, et al. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 2006;12:240-245.
12. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2003;41: 955-963.
13. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004;109:2213-2220.
14. Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 2009;84:164-172.
15. Wada T, Ohshima S, Fujisawa E, et al. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology 2009;150:1662-1669.
16. Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and highfructose diet. Endocrinology 2010;151:2040-2049.
17. Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep 2010;12:252-257.
18. Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 2013;15:59-70.
19. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. [erratum appears in J Am Coll Cardiol 2002;39:1082].
20. J Am Coll Cardiol 2002;39:257-265
21. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011;300:H2-12.
22. Eriksen M. Effect of pulsatile arterial diameter variations on blood flow estimated by Doppler ultrasound. Med Biol Eng Comput 1992;30:46-50.
23. Mitchell GF, Parise H, Vita JA, et al. Local shear stress and brachial artery flow-mediated dilation: The Framingham Heart Study. Hypertension 2004;44:134-139.
24. Milne GL, Sanchez SC, Musiek ES, et al. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007;2:221-226.
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
26. Joffe HV, Kwong RY, Gerhard-Herman MD, et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007;92: 2552-2558.
27. Davies JI, Band M, Morris A, et al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004;47: 1687-1694.
28. Garg R, Kneen L, Williams GH, et al. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab 2014;16:268-272.
29. Pelliccia F, Rosano G, Patti G, et al. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. Int J Cardiol 2014;pii:S0167-5273(14)02087-7 DOI: 10. 1016/j. ijcard. 2014. 10. 150. [Epub ahead of print].
30. Suzuki H, Shuto H, Shuto C, et al. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome. Ther Adv Cardiovasc Dis 2012;6:141-147.
31. Sato A, Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2010;24:387-394.
32. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-158.
33. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-597.